Jingxin Pharmaceutical released its 2026 half-year report. Net profit attributable to the parent for the first half was 352 million yuan, down 9.3% year-on-year. Operating revenue was 1.99 billion yuan, down 1.5% year-on-year. Net profit attributable to the parent after deducting non-recurring items was 342 million yuan, down 5.1% year-on-year. Net operating cash flow was 477 million yuan, up 21.4% year-on-year. Earnings per share were 0.4084 yuan. In the second quarter, operating revenue was 1.06 billion yuan, up 0.3% year-on-year. Net profit attributable to the parent was 186 million yuan, down 17.0% year-on-year. Net profit attributable to the parent after deducting non-recurring items was 186 million yuan, down 12.7% year-on-year. As of the end of the second quarter, total assets were 7.953 billion yuan, down 2.1% from the end of the previous year. Net assets attributable to the parent were 6.0 billion yuan, up 2.9% from the end of the previous year. The company said that during the reporting period, the profitability of its main business grew steadily and its product structure continued to improve, with a focus on innovative drug research and development in the psychiatric, neurological, and cardiovascular and cerebrovascular fields. During the reporting period, sales of Dimdazenil capsules reached 153 million yuan, and the share of revenue from innovative drugs steadily increased. Cariprazine hydrochloride capsules received a drug registration certificate in June 2026, becoming the first generic version in China.
Zhejiang Jingxin Pharmaceutical Co LtdFirst-half net profit fell 9.3% year-on-year to 352 million yuan, with Q2 profit down 17.0%.
